Abivax SA: Business Overview, Financials & Competitive Analysis
Abivax SA scores 8/10 on the AskCyborg Cyborg Score (Strong). First-in-class anti-inflammatory molecule with blockbuster Phase 3 data in large IBD market with limited competition from novel mechanisms. The company's stock surged by around 580% in August 2025 following dual Phase III success in ulcerative colitis. According to 11 analysts, the average rating for ABVX stock is Strong Buy with.
What is Abivax SA's industry? Abivax SA (abivax.com) operates in Biotechnology / Pharmaceutical. AskCyborg classifies Abivax SA under Biotechnology / Pharmaceutical in its company registry.
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases...
Cyborg Score thesis
First-in-class anti-inflammatory molecule with blockbuster Phase 3 data in large IBD market with limited competition from novel...
Read the full analyst-debate transcript →Get the Latest Abivax SA Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAbivax SA Overview
Pro stress-test →Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Obefazimod, Abivax's lead drug candidate, is the first and only molecule that enhances the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response.
Strategic Profile
Pro stress-test →In August 2025, the stock price of Abivax surged by around 580% following dual Phase III success in ulcerative colitis. Abivax delivered outstanding phase 3 results for obefazimod in ulcerative colitis, with a 16.4% placebo-adjusted clinical remission rate. The company is positioned as a potential market leader in inflammatory bowel disease treatment with a novel mechanism of action.
Competitive Landscape
Pro stress-test →Competitors include Transgene, Regeneron Pharmaceuticals, Astellas Pharma, and Galectin Therapeutics. Abivax differentiates through its first-in-class miR-124 enhancement mechanism versus existing JAK inhibitors and S1P modulators in the IBD space.
Industry Context
Abivax SA operates in Biotechnology / Pharmaceutical.
Key facts
Founded: 2013 · Headquarters: Paris, France · Employees: 69 · Revenue: $10.79M · Market cap: $9.9B